# A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC

> **NCT03392064** · PHASE1 · SUSPENDED · sponsor: **Amgen** · enrollment: 6 (actual)

## Conditions studied

- Small Cell Lung Cancer

## Interventions

- **BIOLOGICAL:** AMG 119

## Key facts

- **NCT ID:** NCT03392064
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2018-09-10
- **Primary completion:** 2028-01-14
- **Final completion:** 2028-01-14
- **Target enrollment:** 6 (ACTUAL)
- **Why stopped:** Study on enrollment hold, may potentially resume. No active subjects on trial.
- **Last updated:** 2025-10-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03392064

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03392064, "A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03392064. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*